Hercules Capital, Inc. (NYSE: HTGC) announced on November 8, 2024, that it has entered into an agreement to provide Disc Medicine, Inc. with up to $200 million in non-dilutive debt financing. This facility aims to significantly increase Disc Medicine's future financial and operational flexibility.
Under the terms of the agreement, $30 million was drawn at closing, with an additional $80 million available at Disc Medicine's sole discretion through the second half of 2026. The funding is designed to support the development across Disc Medicine's portfolio, including the potential accelerated approval pathway for bitopertin in EPP.
This financing highlights Hercules Capital's continued investment in the life sciences sector, supporting companies at critical stages of development. The partnership is expected to bolster Disc Medicine's ability to advance its clinical programs without equity dilution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.